{'52WeekChange': 0.2136848,
 'SandP52WeekChange': None,
 'address1': '9393 Towne Centre Drive',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 290.59,
 'askSize': 900,
 'averageDailyVolume10Day': 279737,
 'averageVolume': 467203,
 'averageVolume10days': 279737,
 'beta': 1.80168,
 'beta3Year': None,
 'bid': 116.36,
 'bidSize': 900,
 'bookValue': 15.068,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 120,
 'dayLow': 115.895,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -16.349,
 'enterpriseToRevenue': 1861.585,
 'enterpriseValue': 4389616128,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 114.40257,
 'fiftyTwoWeekHigh': 132.59,
 'fiftyTwoWeekLow': 66.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 29243486,
 'forwardEps': -9.03,
 'forwardPE': -12.9058695,
 'fromCurrency': None,
 'fullTimeEmployees': 111,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.09319,
 'heldPercentInstitutions': 1.00546,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/mirati.com',
 'longBusinessSummary': 'Mirati Therapeutics, Inc., a clinical-stage oncology '
                        'company, develops product candidates to address the '
                        'genetic and immunological promoters of cancer in the '
                        'United States. The company is involved in developing '
                        'sitravatinib, a spectrum-selective kinase inhibitor, '
                        'which is in Phase II clinical for the treatment of '
                        'non-small cell lung cancer (NCSLC); and in Phase Ib '
                        'clinical trial to treat NCSLC patients with Casitas '
                        'B-lineage Lymphoma genetic alterations, as well as '
                        'KRAS G12C inhibitor program for NSCLC adenocarcinoma '
                        'patients, colorectal cancer patients, and other '
                        'cancers. It also develops mocetinostat, an orally '
                        'investigational selective Class I and IV histone '
                        'deacetylase inhibitor that has completed Phase II '
                        'clinical trial in combination with durvalumab for the '
                        'treatment of patients with NSCLC. The company has a '
                        'collaboration and license agreement with BeiGene, '
                        'Ltd. to develop, manufacture, and commercialize '
                        'sitravatinib; and a Clinical Collaboration Agreement '
                        'with Novartis International AG. Mirati Therapeutics, '
                        'Inc. was founded in 1995 and is headquartered in San '
                        'Diego, California.',
 'longName': 'Mirati Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 5086085120,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_121270',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -258999008,
 'nextFiscalYearEnd': 1640908800,
 'open': 118.75,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '858 332 3410',
 'previousClose': 119.73,
 'priceHint': 2,
 'priceToBook': 7.7342715,
 'priceToSalesTrailing12Months': 2156.9487,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 120,
 'regularMarketDayLow': 115.895,
 'regularMarketOpen': 118.75,
 'regularMarketPreviousClose': 119.73,
 'regularMarketPrice': 118.75,
 'regularMarketVolume': 214859,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 43502800,
 'sharesPercentSharesOut': 0.1144,
 'sharesShort': 4992606,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5146958,
 'shortName': 'Mirati Therapeutics, Inc.',
 'shortPercentOfFloat': 0.1312,
 'shortRatio': 10.16,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'MRTX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -6.566,
 'twoHundredDayAverage': 96.11611,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'e9c1e7b8-e997-3ba1-9039-56fe605a96ca',
 'volume': 214859,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.mirati.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92121'}